This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Darden Restaurants (DRI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Darden Restaurants (DRI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DRINegative Net Change PLAYPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does Perpetua Resources (PPTA) Have the Potential to Rally 27.71% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Perpetua Resources (PPTA) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PPTAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Omnicell (OMCL) Could Surge 39.36%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OMCLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 106.84% Upside in Exodus Movement, Inc. (EXOD): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Exodus Movement, Inc. (EXOD) points to a 106.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EXODNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Analysts Estimate General Mills (GIS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
General Mills (GIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GISPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Think Great Lakes Dredge & Dock (GLDD) Could Surge 27.23%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 27.2% upside potential for Great Lakes Dredge & Dock (GLDD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GLDDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 26.52% Upside in Mosaic (MOS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 26.5% upside potential for Mosaic (MOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MOSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ATXSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Carpenter (CRS) Climb 26.25% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 26.3% upside potential for Carpenter (CRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SIONPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SDGRNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Sezzle Inc. (SEZL) Could Rally 49.63%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 49.6% in Sezzle Inc. (SEZL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SEZLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 35.64% Upside in Inogen (INGN): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
INGNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 39.8% Upside in Photronics (PLAB): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 39.8% upside potential for Photronics (PLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PLABNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ALGSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 26.76% Upside in Ategrity Specialty Insurance Company Holdings (ASIC): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Ategrity Specialty Insurance Company Holdings (ASIC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ASICPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Epam (EPAM) Could Rally 26.37%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Epam (EPAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EPAMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 62.07% Upside in Red Robin (RRGB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Red Robin (RRGB) points to a 62.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
RRGBNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MRSNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PHATPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 34.02% Upside in Salesforce.com (CRM): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Salesforce.com (CRM) points to a 34% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DMACPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Solaris Resources Inc. (SLSR) Could Surge 100.94%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 100.9% upside potential for Solaris Resources Inc. (SLSR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SLSRNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Build-A-Bear (BBW) Could Rally 34.16%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 34.2% upside potential for Build-A-Bear (BBW). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BBWNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate